scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1028994264 |
P356 | DOI | 10.1186/1742-6405-4-6 |
P932 | PMC publication ID | 1828738 |
P698 | PubMed publication ID | 17352834 |
P5875 | ResearchGate publication ID | 6453953 |
P50 | author | Somnuek Sungkanuparph | Q75156091 |
P2093 | author name string | Weerawat Manosuthi | |
Sirirat Likanonsakul | |||
Sukanya Chimsuntorn | |||
P2860 | cites work | Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine | Q31928274 |
Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis | Q34093134 | ||
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients | Q34191241 | ||
The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients. | Q39525270 | ||
Clinical experience with non-nucleoside reverse transcriptase inhibitors. | Q41694988 | ||
Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy | Q43672041 | ||
High hepatotoxicity rate seen among HAART patients | Q43730857 | ||
Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs | Q44198482 | ||
Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis | Q44323557 | ||
Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. | Q44365647 | ||
A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients | Q44620199 | ||
Hepatotoxicity associated with nevirapine use. | Q44799933 | ||
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study | Q44849439 | ||
Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less | Q44997968 | ||
Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study | Q45134803 | ||
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects | Q45270618 | ||
Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection | Q45751686 | ||
Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country | Q47298369 | ||
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel | Q50105738 | ||
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). | Q53851252 | ||
Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study | Q57075689 | ||
Predictors of optimal virological response to potent antiretroviral therapy | Q73064663 | ||
DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy | Q77595515 | ||
Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin | Q79738909 | ||
Initiation of highly active antiretroviral therapy in advanced AIDS with CD4 < 50 cells/mm3 in a resource-limited setting: efficacy and tolerability | Q81647605 | ||
Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort | Q83323867 | ||
P921 | main subject | nevirapine | Q263713 |
lamivudine | Q422631 | ||
stavudine | Q423984 | ||
anti-retroviral agent | Q50430310 | ||
P304 | page(s) | 6 | |
P577 | publication date | 2007-03-13 | |
P1433 | published in | AIDS Research and Therapy | Q15755474 |
P1476 | title | Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3. | |
P478 | volume | 4 |